Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + docetaxel + oxaliplatin + 5-fluorouracil + leucovorin
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination drug regimen comprised of five agents: - **pembrolizumab**: a monoclonal antibody immune checkpoint inhibitor targeting programmed cell death 1 receptor (PD-1), enhancing T-cell mediated anti-tumor immune response. - **docetaxel**: a cytotoxic small molecule chemotherapy of the taxane class, inhibiting microtubule depolymerization, blocking cell division. - **oxaliplatin**: a platinum-based small molecule chemotherapy, causing DNA crosslinking and apoptosis. - **5-fluorouracil (5-FU)**: a pyrimidine analog small molecule antimetabolite, inhibiting thymidylate synthase, blocking DNA synthesis. - **leucovorin (folinic acid)**: a folate analog used to potentiate 5-FU by stabilizing its binding to thymidylate synthase, enhancing cytotoxicity. This regimen is studied as perioperative therapy for gastric/esophageal/gastroesophageal junction adenocarcinoma in combination with pembrolizumab to increase pathologic response rates, disease-free survival, and overall survival; it is also under investigation for other solid tumors, particularly when combining immunotherapy and multi-agent chemotherapy[1][5].
- Other names
- pembrolizumab + docetaxel + oxaliplatin + 5-fluorouracil + leucovorin
02
Targets
TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pembrolizumab + docetaxel + oxaliplatin + 5-fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + docetaxel + oxaliplatin + 5-fluorouracil + leucovorin.